(COCP) Cocrystal Pharma - Ratings and Ratios

Cocrystal Pharma, Inc. is a biotechnology company specializing in the discovery and development of antiviral therapies for severe and chronic viral diseases. Utilizing structure-based drug design, the company creates small-molecule inhibitors targeting viral replication. Its pipeline includes CC-31244, a non-nucleoside polymerase inhibitor for hepatitis C virus (HCV) in Phase II trials, and CC-42344, a PB2 inhibitor for influenza in Phase I. Additionally, Cocrystal is developing inhibitors for norovirus, a leading cause of gastroenteritis, leveraging a collaboration with Kansas State University. The company has also partnered with Merck to develop influenza A/B antivirals, enhancing its credibility in the field.

Technically, COCPs stock is below its 20 and 50-day SMAs, indicating bearish momentum. The low average volume and ATR suggest reduced volatility. Fundamentally, with a $17.6M market cap and high P/S ratio, the stock may be undervalued despite its early-stage revenue generation. The 3-month forecast anticipates sideways movement with potential dips, yet upside potential exists pending positive clinical developments.